References
- Lin CC, Xu C, Yeh LT, et al. (2006). Pharmacokinetics and pharmacodynamics of pradefovir mesylate, a liver-targeting pro-drug of PMEA, in HBV patients [Online]. European Association for the Study of Liver Diseases. Available at: http://www.natap.org/2006/EASL/EASL_31.htm. [last accessed 26–30 Apr 2006]
- Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543–52
- Duan J, Xie Y, Luo H, et al. (2014). Transport characteristics of isorhamnetin across intestinal Caco-2 cell monolayers and the effects of transporters on it. Food Chem Toxicol: Int J Publ Br Ind Biol Res Assoc 66:313–20
- Duan L, Yan Y, Sun YB, et al. (2013). Contribution of TRPV1 and multidrug resistance proteins in the permeation of capsaicin across different intestinal regions. Int J Pharm 445:134–40
- Gotoh Y, Kamada N, Momose D. (2005). The advantages of the Ussing chamber in drug absorption studies. J Biomol Screen 10:517–23
- Kadono K, Koakutsu A, Naritomi Y, et al. (2014). Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method. Xenobiotica 44:511–21
- Lin CC, Fang C, Benetton S, et al. (2006). Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother 50:2926–31
- Lin CC, Xu C, Zhu NQ, et al. (2005). Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys. Antimicrob Agents Chemother 49:925–30
- Lin CC, Yeh LT, Vitarella D, et al. (2004). Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antivir Chem Chemother 15:307–17
- Matsuda Y, Konno Y, Satsukawa M, et al. (2012). Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats. Drug Metab Dispos: Biol Fate Chem 40:2231–8
- Mudra DR, Borchardt RT. (2010). Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism. J Pharm Sci 99:982–98
- Naritomi Y, Terashita S, Kimura S, et al. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–24
- Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos: Biol Fate Chem 27:1350–9
- Reddy KR, Matelich MC, Ugarkar BG, et al. (2008). Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J Med Chem 51:666–76
- Vandekerkhof EG, Degraaf IAM, Groothuis GMM. (2007). In vitro methods to study intestinal drug metabolism. Curr Drug Metab 8:658–75
- Venkatakrishnan K, Vonmoltke LL, Greenblatt DJ. (2001). Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149–79
- Wahajuddinraju KS, Singh SP, Taneja I. (2014). Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine. Antimicrob Agents Chemother 58:489–94